Viewing Study NCT06354439



Ignite Creation Date: 2024-05-06 @ 8:22 PM
Last Modification Date: 2024-10-26 @ 3:26 PM
Study NCT ID: NCT06354439
Status: RECRUITING
Last Update Posted: 2024-04-09
First Post: 2024-04-01

Brief Title: Use of Letrozole for Ectopic Pregnancy
Sponsor: Hospital de Clinicas de Porto Alegre
Organization: Hospital de Clinicas de Porto Alegre

Study Overview

Official Title: Use of Letrozole in the Treatment of Early Ectopic Pregnancy
Status: RECRUITING
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: EcZOL
Brief Summary: A randomized clinical trial using oral letrozole 10mgday for 7 days for treating early cases of ectopic pregnancy compared to intramuscular methotrexate
Detailed Description: This is a multicenter randomized clinical trial on the use of letrozole in the medical treatment of tubal ectopic pregnancy Tubal ectopic pregnancy is an abnormal pregnancy in the fallopian tube They occurred in about 8 of all pregnancies presenting to the emergency department Methotrexate MTX administered systemically intramuscularly is a widely used medication for the treatment of unruptured tubal ectopic pregnancies and has been recommended as first-line treatment for early cases of ectopic pregnancy

Letrozole is an aromatase inhibitor and can suppress estradiol levels Some recent studies have shown that its use can be applied in cases of ectopic pregnancy

The aim of this non-inferiority clinical trial is to verify that letrozole treatment is non-inferior to methotrexate treatment in women with early ectopic pregnancy who are hemodynamically stable

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None